Atea Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2018 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2018 - 2019
Net Income	-168.39	-135.96	-115.91	121.19	-10.95	Upgrade
Depreciation & Amortization	0.42	0.42	0.26	0.03	0.02	Upgrade
Loss (Gain) From Sale of Investments	-11.82	-15.45	-5.47	-	-	Upgrade
Stock-Based Compensation	51.77	49.43	46.72	39.62	7.46	Upgrade
Change in Accounts Receivable	-	-	-	-	-5.82	Upgrade
Change in Accounts Payable	0.21	1.7	-1.98	10.29	-0.49	Upgrade
Change in Unearned Revenue	-	-	-	-301.37	301.37	Upgrade
Change in Other Net Operating Assets	-7.68	14.46	-44.6	43.23	5.14	Upgrade
Operating Cash Flow	-135.5	-85.4	-120.98	-87.01	296.73	Upgrade
Capital Expenditures	-	-	-1.94	-0	-0.03	Upgrade
Investment in Securities	56.11	40.3	-453.47	-	-	Upgrade
Investing Cash Flow	56.11	40.3	-455.41	-0	-0.03	Upgrade
Issuance of Common Stock	0.27	0.26	0.37	1.47	317.63	Upgrade
Other Financing Activities	-	-	-	-	-0.02	Upgrade
Financing Cash Flow	0.27	0.26	0.37	1.47	531.75	Upgrade
Net Cash Flow	-79.13	-44.84	-576.02	-85.54	828.46	Upgrade
Free Cash Flow	-135.5	-85.4	-122.93	-87.01	296.71	Upgrade
Free Cash Flow Margin	-	-	-	-24.76%	610.10%	Upgrade
Free Cash Flow Per Share	-1.61	-1.02	-1.48	-0.99	13.74	Upgrade
Levered Free Cash Flow	-39.55	-9.76	-69.52	-127.65	300.81	Upgrade
Unlevered Free Cash Flow	-39.55	-9.76	-69.52	-127.65	300.81	Upgrade
Change in Net Working Capital	9.1	-15.72	45.11	253.78	-300.25	Upgrade

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q